相关实验视频

Updated: May 22, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

营养状况及其对治疗耐受性的影响,非小细胞肺癌患者接受奥西默蒂尼布治疗

Claudia Barca-Díez^1,2, Regina Palmeiro-Carballa³, Susana Castro-Luaces^1,4

¹Pharmacy Department, University Hospital Complex of Vigo, 36312 Vigo, Spain.

|March 13, 2025

概括

营养不良是常见的非小细胞肺癌 (NSCLC) 患者接受 osimertinib. 较低的肌肉质量与增加的毒性有关,强调需要营养支持以改善结果.

科学领域:

在瘤学瘤学.
营养科学营养科学
药理学药理学是指药理学的学科.

背景情况:

非小细胞肺癌 (NSCLC) 是一种流行恶性瘤,具有显著的发病率和死亡率.
营养问题,包括营养不良,影响35-65%的NSCLC患者,影响预后和生活质量.
奥西默提尼布是NSCLC的关键治疗方法,但它对营养状况的影响需要研究.

研究的目的:

评估接受 osimertinib.com 的 NSCLC 患者的营养状况和身体组成.
为了确定这种患者群体中萨尔科佩尼亚,前萨尔科佩尼亚和迪纳佩尼亚的患病率.
探索剂量限制性毒性 (DLT),营养状况和生活质量 (EQ-5D) 之间的关系.

主要方法:

一项涉及25名成年NSCLC患者的横截面观察性研究,这些患者接受了osimertinib治疗.
评估人体参数,身体组成 (生物阻抗分析) 和肌肉功能 (动力学).
使用EQ-5D尺度对生活质量的评估.

主要成果:

36%的患者营养不良;观察到的是sarcopenia (4%),presarcopenia (8%) 和dynapenia (20%).
患有剂量限制性毒性 (DLT) 患者的无脂肪质量和无脂肪质量指数显著降低.
建议减少肌肉质量和增加DLT之间的相关性.

结论:

早期,个性化的营养干预对于接受 osimertinib 的 NSCLC 患者至关重要.
优化营养状况可能会改善瘤结果和治疗耐受性.
需要对更大的队列和纵向设计进行进一步的研究来验证这些发现.

关键词:

身体构成身体组成剂量限制性毒性作用这种疾病叫做dynapenia.营养不良营养不良营养不良其他非小细胞肺癌.奥西米尔丁尼布 (osimertinib) 是一种这种类型的麻症是sarcopenia.

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

相关概念视频

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...